Rua Bioscience Ltd. (RUA) Stock Price & Analysis

1 Followers

RUA Stock Chart & Stats

NZ$0.03NZ$0.00(0.00%)

At close: Nov 11 4:45 PM GMT+13

Day’s Range: NZD 0.03 - NZD 0.03
52-Week Range: NZD 0.03 - NZD 0.04
Previous Close: NZD 0.03
Volume: N/A
Average Volume (3M): 107.08K
Market Cap: NZD 11.77M
Enterprise Value: NZD 10.73M
Total Cash (Recent Filing): NZD 533.70K
Total Debt (Recent Filing): NZD 1.76M
Price to Earnings (P/E): ―
Beta: 1.28
Next Earnings: Mar 04, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth

Revenue is scaling across consecutive years, indicating improving commercial traction for Rua’s medicinal cannabis products. Continued top-line expansion can broaden operating leverage, support market development, and provide a larger base from which future profitability may eventually emerge.

Balance Sheet Support

Although leverage has increased, positive equity and assets materially exceeding debt provide a measure of balance-sheet resilience. This financial support may help the company continue developing products and serving regulated markets while it works toward improving operating performance.

Integrated Business Model

Coverage of the medicinal cannabis value chain gives Rua capabilities spanning cultivation, formulation, and regulated supply rather than relying on a single activity. Its prescription and clinically oriented focus also aligns the business with therapeutic use and approved-market distribution.

Bears Say

Persistent Losses

Persistent large losses and deeply negative net margins show that revenue growth has not yet translated into an economically sustainable business. This weak earnings profile limits internally funded expansion and leaves profitability highly dependent on future improvement in costs, pricing, or scale.

Ongoing Cash Burn

The company continues to consume cash in both operations and free cash flow, meaning current activities do not self-fund. Ongoing burn can constrain investment flexibility and increase the importance of external financing or other capital support until losses are reduced.

Weak Capital Efficiency

Rising leverage alongside sharply negative return on equity indicates that additional capital is not yet producing adequate returns. This combination can reduce financial flexibility over the medium term and makes successful execution and improved operating economics increasingly important.

Rua Bioscience Ltd. News

Rua Bioscience Director Anna Stove Raises Shareholding via New Share Issue

The latest update is out from Rua Bioscience Ltd. ( ($NZ:RUA) ). Rua Bioscience director Anna Stove has increased her shareholding in the company through the issue of 160,000 new

2w agoRUA

Rua Bioscience Director Boosts Shareholding Through New Share Issue

Rua Bioscience Ltd. ( ($NZ:RUA) ) has shared an announcement. Rua Bioscience director Antony Barclay has increased his holding in the company through the issue of 160,624 new ordinary shares

2w agoRUA

Rua Bioscience Director Increases Stake Through New Share Issue

The latest announcement is out from Rua Bioscience Ltd. ( ($NZ:RUA) ). Rua Bioscience has disclosed a change in director Panapa Tewheru Ehau’s relevant interest in the company’s ordinary shares,

2w agoRUA

Rua Bioscience director increases shareholding through new share issue

Rua Bioscience Ltd. ( ($NZ:RUA) ) has issued an update. Rua Bioscience has disclosed an increase in director Teresa Farac-Ciprian’s shareholding following the issue of 85,000 new ordinary shares at

2w agoRUA

Rua Bioscience completes rights offer, lifts share count 11.7%

Rua Bioscience Ltd. ( ($NZ:RUA) ) has provided an update. Rua Bioscience Limited has expanded its ordinary share capital through a pro-rata renounceable rights offer, issuing 39,648,249 new shares at

3w agoRUA

Rua Bioscience wins strong shareholder backing for board and new capital-raising mandate

The latest update is out from Rua Bioscience Ltd. ( ($NZ:RUA) ). Rua Bioscience shareholders endorsed all six ordinary resolutions at the company’s virtual 2026 annual meeting, including the re-election

3w agoRUA

Rua Bioscience flags strong FY26 growth and major UK export deal at virtual AGM

Rua Bioscience Ltd. ( ($NZ:RUA) ) has provided an announcement. Rua Bioscience has released its presentation slides and commentary for its virtual annual shareholders’ meeting, highlighting strong revenue growth and

3w agoRUA

Rua Bioscience Raises NZ$1m in Rights Offer, Seeks Further Capital for UK Growth

Rua Bioscience Ltd. ( ($NZ:RUA) ) just unveiled an announcement. Rua Bioscience has closed a 1-for-3 renounceable rights offer at NZ$0.025 per share, raising about NZ$1.0 million from existing shareholders

3w agoRUA

Rua Bioscience taps Curaleaf for UK medicinal cannabis expansion

Rua Bioscience Ltd. ( ($NZ:RUA) ) has issued an announcement. Rua Bioscience has signed a sales and distribution agreement with Curaleaf Laboratories to bring its New Zealand-grown medicinal cannabis products

4w agoRUA

Rua Bioscience moves into medicinal MDMA with PharmAla partnership

Rua Bioscience Ltd. ( ($NZ:RUA) ) has provided an announcement. Rua Bioscience has signed a distribution and licence agreement with Toronto-based PharmAla Biotech to import, distribute and sell pharmaceutical-grade LaNeo

1M agoRUA

RUA FAQ

What was Rua Bioscience Ltd.’s price range in the past 12 months?

Rua Bioscience Ltd. lowest stock price was NZ$0.03 and its highest was NZ$0.04 in the past 12 months.

What is Rua Bioscience Ltd.’s market cap?

Rua Bioscience Ltd.’s market cap is NZ$11.77M.

When is Rua Bioscience Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Rua Bioscience Ltd.’s earnings last quarter?

Rua Bioscience Ltd. released its earnings results on Aug 27, 2026. The company reported -NZ$0.004 earnings per share for the quarter.

Is Rua Bioscience Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Rua Bioscience Ltd. pay dividends?

Rua Bioscience Ltd. does not currently pay dividends.

What is Rua Bioscience Ltd.’s EPS estimate?

Rua Bioscience Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rua Bioscience Ltd. have?

Rua Bioscience Ltd. has 452,588,930 shares outstanding.

What happened to Rua Bioscience Ltd.’s price movement after its last earnings report?

Rua Bioscience Ltd. reported an EPS of -NZ$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Rua Bioscience Ltd.?

Currently, no hedge funds are holding shares in NZ:RUA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description